Please login to the form below

Not currently logged in
Email:
Password:

Par to acquire Indian generics firm

US-based Par Pharmaceutical has entered into a definitive agreement to acquire India's Edict Pharmaceuticals, a privately held developer and manufacturer of solid oral dosage generic pharmaceuticals

The US-based speciality pharma company Par Pharmaceutical has entered into a definitive agreement to acquire India's Edict Pharmaceuticals, a privately held developer and manufacturer of solid oral dosage generic pharmaceuticals.

Par will pay up to $37.6m in cash for the company, as well as making repayment of certain additional pre-close indebtedness.  The transaction is expected to be completed by the end of this year and to be accretive to Par's earnings in 2013.

Par was attracted to Edict largely because of the Indian company's "highly-skilled research and development team and strong product pipeline focused on niche first-to-file, first-to-market formulations," the US firm said.

Edict currently has seven abbreviated new drug applications (ANDAs) for generic products under its own name pending with the US Food and Drug Administration, as well as one ANDA filed in the US in the name of a development partner, and another 14 generic products in various stages of development.

Edict is focused entirely on developing and manufacturing products for export to the US and other regulated markets, offering "US standards at Indian costs," according to the company's promotional materials.

Par and Edict have already collaborated on a number of Par's generic products and have a longstanding working relationship, the companies noted.

24th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics